HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Cardiology8713 papers

Hypertrophic cardiomyopathy

Last edited: 4/23/2026

Overview

Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by left ventricular hypertrophy, often leading to diastolic dysfunction and potentially life-threatening complications such as outflow tract obstruction and arrhythmias 1 66.

Diagnosis

Echocardiography: Essential for initial diagnosis, assessing left ventricular wall thickness, septal curvature, and outflow tract gradients 1 3 10 44.

Cardiac MRI: Provides detailed assessment of myocardial fibrosis via ECV and scar architecture, aiding in risk stratification 5 51 63.

Tissue Doppler Imaging: Utilizes Tei index for evaluating myocardial performance 4.

Genetic Testing: Recommended for identifying pathogenic variants, especially in familial cases 29 55.

Electrocardiogram (ECG): Useful for identifying specific patterns and integrating into risk stratification tools 55.

Management

Medical Therapy:

- Beta-blockers: First-line for symptom management and reducing outflow tract obstruction 1 66. - Calcium Channel Blockers: Alternative for those intolerant to beta-blockers 1. - Mavacamten/Aficamten: Novel myosin inhibitors effective in reducing outflow tract gradients and improving symptoms 6 17 31 53.

Surgical Interventions:

- Alcohol Septal Ablation (ASA): Effective for reducing outflow tract obstruction 3 16. - Surgical Myectomy: Gold standard for severe, refractory cases 1 18.

Device Therapy:

- Implantable Cardioverter-Defibrillators (ICDs): Recommended for primary prevention of sudden cardiac death in high-risk patients 1 21.

Special Populations

Pediatrics: Tailored exercise programs and careful monitoring are essential; mavacamten shows promise in adolescents 25 68.

Elderly: Consider comorbidities and functional status; outcomes may vary with center experience 19 59.

Comorbidities: Management of coronary artery disease and mitral regurgitation is crucial, as these can significantly impact prognosis 4 49.

Key Recommendations

Utilize multi-modality imaging for comprehensive assessment and risk stratification in HCM patients (Evidence: Strong 1 5 10).

Consider mavacamten or aficamten for symptomatic patients with obstructive HCM to reduce outflow tract gradients and improve symptoms (Evidence: Moderate 6 17 31).

Implement genetic testing for familial screening and personalized management strategies (Evidence: Moderate 29 55).

Use ICDs for primary prevention in high-risk patients to mitigate sudden cardiac death risk (Evidence: Strong 1 21).

Tailor exercise programs for pediatric patients with HCM to balance activity and safety (Evidence: Expert opinion 25).

References

Showing 100 most recent of 2808 indexed papers.

1 Cardim N, Haugaa K, Mohiddin SA, Hinojar R, Hirsch A, Szabo L et al.. Role of multi-modality cardiac imaging in the management of patients with hypertrophic cardiomyopathy in 2025. A Clinical Consensus Statement of the European Association of Cardiovascular Imaging (EACVI) of the ESC. European heart journal. Cardiovascular Imaging 2026. link 2 Anifowose A, Tagliafierro M, Mahdi G, Hussein S, Baudo M, Caldonazo T et al.. Interventions for Hypertrophic Obstructive Cardiomyopathy: Defining the Gold Standard, Assessing Durability, and Guiding Patient Selection. Medical sciences (Basel, Switzerland) 2026. link 3 Lee JE, Koo HJ, Lee SA, Hyun J, Yoo JS, Yang DH et al.. Impact of preoperative computed tomography planning on surgical outcomes in patients with obstructive hypertrophic cardiomyopathy: A prospective cohort study. The Journal of thoracic and cardiovascular surgery 2026. link 4 Naseri A, Ider M, Sahin HB, Durgut MK, Iyigun SS, Guzelbektes H. Clinical value of the tissue Doppler derived index of myocardial performance (Tei index) in cats with hypertrophic cardiomyopathy. Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology 2026. link 5 Gkizas C, Longere B, Bechrouri S, Ridon H, Musso AR, Haidar M et al.. Photon-counting CT myocardial extracellular volume: A non-invasive biomarker for fibrosis in patients with hypertrophic cardiomyopathy. Diagnostic and interventional imaging 2026. link 6 So ACF, Davison KA, Hecker T, Moriswala R, Pasupathy S, Shah RJ et al.. Mavacamten in Obstructive Hypertrophic Cardiomyopathy-A First Australian Experience. Heart, lung & circulation 2026. link 7 Erzeel J, Dhont S, van Es M, Ulgar D, Bertrand P, Mullens W et al.. Role of provocation and exercise imaging for the identification of candidates for cardiac myosin inhibitors. ESC heart failure 2026. link 8 Razak ZA, Westaby J, Sheppard MN. Sudden perioperative death post aortic valve replacement with autopsy showing hypertrophic cardiomyopathy in elderly female. International journal of legal medicine 2026. link 9 Kiselev E, Agyapong W, Jürgens B, Mohr E, Chatterjee S, Hunkler HJ et al.. Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy. British journal of pharmacology 2026. link 10 Pearlman A, Hellyer R, Burns C, Medi C, Gray B. Focused Transthoracic Echocardiogram Surveillance Protocol for Hypertrophic Cardiomyopathy Patients on Mavacamten Therapy. Heart, lung & circulation 2026. link 11 Zhang X, Xie Y, Fang L, Xu J, Yang Y, He Z et al.. The evolving clinical practice of septal reduction therapy in hypertrophic obstructive cardiomyopathy. International journal of surgery (London, England) 2026. link 12 Rossano J, Canter C, Wolf C, Favatella N, Lockman J, Puli S et al.. Mavacamten in symptomatic adolescent patients with obstructive hypertrophic cardiomyopathy: design of the phase 3 SCOUT-HCM trial. American heart journal 2026. link 13 Li R, Wang B, Shan B, Sun M, Ta S, Zhao J et al.. Application of untargeted plasma metabolomics and machine learning to construct a diagnostic model for hypertrophic cardiomyopathy: a case-control study. Metabolomics : Official journal of the Metabolomic Society 2026. link 14 Wang X, Pabon MA, Makuvire TT, Maimaiti R, Abraham TP, Barriales-Villa R et al.. Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM. Circulation. Heart failure 2026. link 15 Nogueira-Garcia B, Pinheiro D, Gregório C, Caldeira D, Pinto FJ, Brito D. Genotype-phenotype associations in sarcomeric hypertrophic cardiomyopathy associated with mutations in the MYBPC3 gene: Systematic review and meta-analysis. Journal of cardiology 2026. link 16 Veselka J, Liebregts M, Cooper R, Faber L, Januska J, Krejci J et al.. Impact of centre experience on complete clinical and haemodynamic response after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. International journal of cardiology 2026. link 17 Patel N, Gaonkar M, Pampana A, Shetty NS, Vekariya N, Li P et al.. Clinical Outcomes With Mavacamten Use in Patients With Obstructive Hypertrophic Cardiomyopathy Using Real-World Data. Mayo Clinic proceedings 2026. link 18 Osberghaus V, Wustmann K, Heck PB, Georgiev S, Eicken A, Ewert P et al.. Percutaneous Management of Right Ventricular Outflow Tract Obstruction in an Adult Patient After Atrial Switch: A Case for Targeted Infundibular Ablation. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2026. link 19 Mohal JS, Whinnett ZI, Mohiddin SA, Malcolmson J, Elliott P, Ormerod JOM et al.. Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy: The EMORI-HCM Trial. Journal of the American College of Cardiology 2026. link 20 Bonanni F, Ballerini A, Gozzini A, Marchi A, Palinkas ED, Barletta V et al.. Autosomal recessive hypertrophic cardiomyopathy associated with variants in TRIM63. International journal of cardiology 2026. link 21 Abusafia M, Jadam S, Ospina S, Desai MY. Hypertrophic Cardiomyopathy: Patient Selection, Referral Timing, and Advanced Therapy Options. Heart failure clinics 2026. link 22 Testa L, Arzuffi L, Popolo Rubbio A, Brambilla N, Maisano F, Agricola E et al.. Transcatheter Edge-to-Edge Repair for SAM-Related Mitral Regurgitation in Patients With HCM: The TRANSPARENT Registry. JACC. Cardiovascular interventions 2026. link 23 Grosso G, Schober KE. Effect of echocardiographic imaging view and methods on left ventricular wall-thickness measurements in normal cats and cats with hypertrophic cardiomyopathy. Journal of veterinary internal medicine 2026. link 24 Fahim M, Eldawud D, Wahadneh O, Wang R, Gorantla A, Sharma N et al.. Mavacamten and Aficamten in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Trials. The American journal of cardiology 2026. link 25 Wanner J, Burstein D, Paridon S, Shah M, O'Malley S, Lin KY et al.. Feasibility of an Individualized Exercise Training Program for Children with Hypertrophic Cardiomyopathy. Pediatric cardiology 2026. link 26 Lin B, Wang J, Li C, Wang S, Shen M, Hu L et al.. CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy. Circulation 2026. link 27 Peters M, Schweitzer M, Galazka P. Multimodality Imaging in Hypertrophic Cardiomyopathy. Cardiology clinics 2026. link 28 Lombardi M, Barki M, Spartano L, Lazzeroni D, Benedetti G, Pisano A et al.. miR-144 targets in myocardial hypertrophy and coronary microvascular dysfunction in hypertrophic cardiomyopathy: molecular research meets imaging. Basic research in cardiology 2026. link 29 Killian M, Ranganathan D, Moore D, Gallagher M, Ochoa JP, Howard S et al.. Predictors for increasing genetic testing yields in hypertrophic cardiomyopathy. Irish journal of medical science 2026. link 30 Marwaha K, Mody B, Holland N, Lane M, Shoemake BD, Singh N et al.. Genetic diversity and molecular mechanisms in hypertrophic cardiomyopathy: toward personalized therapy. American journal of physiology. Heart and circulatory physiology 2026. link 31 Wang A, Garcia-Pavia P, Masri A, Merkely B, Nassif ME, Peña-Peña ML et al.. Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. Journal of the American College of Cardiology 2026. link 32 Ma X, Tang Y, Chen X, Yang S, Wang J, Yang K et al.. Feature Tracking-Derived Global Longitudinal Strain Enhances Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy. JACC. Cardiovascular imaging 2026. link 33 Wiethoff I, Witlox WJA, Evers SMAA, Michels M, Hiligsmann M. Model-Based Economic Evaluation of the First-in-Class Myosin Inhibitor Mavacamten Versus Care as Usual in Obstructive Hypertrophic Cardiomyopathy Patients from a Dutch Societal Perspective. PharmacoEconomics 2026. link 34 Grinberg T, Aviv Y, Shiyovich A, Vronsky D, Lerman TT, Pravda NS et al.. Coronary artery disease characterization and plaque morphology in patients with hypertrophic cardiomyopathy. The American journal of medicine 2026. link 35 Bilen O, Adler A, Bastiaenen R, MacNamara JP, Paratz E, Maor E et al.. Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM. Circulation. Genomic and precision medicine 2026. link 36 Song Y, Hu M, Ren H, Fang Q, Zheng T, Feng Z et al.. Incremental prognostic value of epicardial adipose tissue volume and thickness assessed by cardiac MRI in hypertrophic cardiomyopathy. European heart journal. Cardiovascular Imaging 2026. link 37 Suwa K, Ohno K, Satoh T, Sato R, Iguchi K, Maekawa Y. Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: Long-Term Follow-Up of Deformations and Hemodynamics. Journal of magnetic resonance imaging : JMRI 2026. link 38 Patel N, Gaonkar M, Pampana A, Dhaliwal JS, Vekariya N, Shetty NS et al.. Cardiovascular Health and Outcomes in Carriers With Genetic Variants of Hypertrophic Cardiomyopathy. Mayo Clinic proceedings 2026. link 39 Zampieri M, Saberi S, D'Ascenzi F, Papadakis M, Pelliccia A, Olivotto I. Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation. European heart journal 2026. link 40 Koch V, Ochs AT, Martin S, Vogl T, Ochs MM, Leistner DM et al.. Heterogeneous Myocardial Adaptation to Pressure Overload Reveals a Spared, Vulnerable Segment Identified by Multiparametric Cardiac MRI. NMR in biomedicine 2026. link 41 Gao YP, Fan YT, Cheng XQ, Huang PN, Liu HY, Bi XJ et al.. Incremental Value of NT-proBNP Over HCM-AF Score in Risk Stratification for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. Clinical cardiology 2026. link 42 Chaudhry WR, McWilliam C, Berg J, Choy AM. Characterising the phenotype and ‍outcomes of cascade-tested relatives of probands with ‍hypertrophic cardiomyopathy. Open heart 2026. link 43 Ozbay B, Wong TC, Estes NAM, Katz WE, Suffoletto MS, Green G et al.. Effect of mavacamten and disopyramide on left ventricular mechanical dispersion and life-threatening arrhythmia in obstructive hypertrophic cardiomyopathy. European heart journal. Cardiovascular Imaging 2026. link 44 Sommese RF, Levi SM, Brown J, Polivkova J, Byrnes LJ, Kue R et al.. Discovery of small molecule modulators of the thin filament that alter the contractile profile in a hypertrophic cardiomyopathy engineered tissue model. The Journal of biological chemistry 2026. link 45 Niemiec M, Stec M, Grzybowski J, Cegłowska U, Wiśniewska A, Hałgas K et al.. What Do We Know About Hypertrophic Cardiomyopathy in Poland in the Period 2016-2021 Based on Data From the Public Health System?. International journal of public health 2026. link 46 Steitieh D, Gupta J, Kim R. Use of artificial intelligence in the multimodal evaluation of ischemia in patients with hypertrophic cardiomyopathy. The international journal of cardiovascular imaging 2026. link 47 Polizzi R, Canciello G, Ordine L, di Napoli S, Pacella D, Moscano L et al.. Reverse septal curvature in hypertrophic cardiomyopathy: Implications for function, structure and arrhythmic risk. International journal of cardiology 2026. link 48 Bové T, Impens L, Leleu J, Timmermans F, François K. Concomitant Mitral Valve Surgery During Surgical Treatment of Hypertrophic Obstructive Cardiomyopathy. The American journal of cardiology 2026. link 49 Obayashi Y, Kato T, Shiomi H, Nakatsuka K, Kitaoka H, Sakata Y et al.. Prognostic Implications of Mitral Regurgitation Across Hypertrophic Cardiomyopathy Subtypes: A Report From REVEAL-HCM Study. Circulation. Heart failure 2026. link 50 Tian Y, Zhang H, Yang S, Chu C, Jing H, Gong C et al.. Percutaneous Endocardial Septal Pulsed Field Ablation for Hypertrophic Obstructive Cardiomyopathy: A Case Report. Pacing and clinical electrophysiology : PACE 2026. link 51 Francia P, Falasconi G, Musumeci MB, Biagini E, Freitas P, Penela D et al.. Scar architecture as a structural biomarker of ventricular arrhythmias and sudden cardiac death in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance study. European heart journal. Cardiovascular Imaging 2026. link 52 Wang W, Tian Y, Wang C, Yang X. Identification of Cuproptosis-Associated Biomarker Candidates in Hypertrophic Cardiomyopathy via Machine Learning and Multi-Omics Integration. Applied biochemistry and biotechnology 2026. link 53 Nagy V, Rácz G, Takács H, Boda K, Polestyuk B, Schvartz N et al.. Mavacamten effectively reduces > 100 mmHg left ventricular outflow tract gradients as early as one week of treatment in obstructive hypertrophic cardiomyopathy. International journal of cardiology 2026. link 54 Sharkey A, Ahmed U, Manji AA, Mahmood F, Saeed S, Valencia J et al.. Peak Gradients and Left Ventricular Outflow Tract Area in Hypertrophic Obstructive Cardiomyopathy:A 3-Dimensional Echocardiography Study. Journal of cardiothoracic and vascular anesthesia 2026. link 55 Hiruma T, Inoue S, Dai Z, Nomura S, Kubo T, Sugiura K et al.. Integrating ECG Into the Mayo Score Enhances Genotype Prediction in Hypertrophic Cardiomyopathy. Journal of the American Heart Association 2026. link 56 Pietsch N, Singh SR, Carrier L. Mechanisms and Therapies of Hypertrophic Cardiomyopathy. Annual review of physiology 2026. link 57 Kim H, Song MJ, Kim J, Kim SM. A machine Learning-Based risk stratification using CMR volumetric and strain parameters in patients with hypertrophic cardiomyopathy. The international journal of cardiovascular imaging 2026. link 58 Chen Y, Lai Y, Fang J, Li R, Yan J, Tan T et al.. Transapical beating-heart approach is advantageous for surgical septal reduction therapy in pediatrics. The Journal of thoracic and cardiovascular surgery 2026. link 59 Reza N, Butzner M, Batra K, Amos Q, Buikema A, Shreay S et al.. Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy. Journal of the American Heart Association 2026. link 60 Masri A, Maron MS, Abraham TP, Nassif ME, Barriales-Villa R, Bilen O et al.. Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy. JACC. Heart failure 2026. link 61 Matsuda J, Takano H, Imori Y, Ishihara K, Sangen H, Kubota Y et al.. Reply to letter to the editor: "Long-term clinical outcomes after alcohol septal ablation for hypertrophic obstructive cardiomyopathy in Japan: a retrospective study". Heart and vessels 2026. link 62 Andrushchuk U, Niavyhlas A, Nesterowicz M, Dzieżyk W, Chrostowski T, Sulima D et al.. Diagnosis and Treatment Guided by 3D Imaging and Modeling: A W-shaped Interventricular Septal Phenotype in Hypertrophic Obstructive Cardiomyopathy. Radiology. Cardiothoracic imaging 2026. link 63 Li J, Zhu L, Liu Y, Han Y, Yuan S, Cao J et al.. Non-contrast multimodal cardiac MRI for predicting coronary microvascular dysfunction in patients with hypertrophic cardiomyopathy. Magnetic resonance imaging 2026. link 64 Schoonvelde SAC, Zwetsloot PP, Hirsch A, Schinkel AFL, Knackstedt C, Germans T et al.. Accelerometry-defined physical activity and quality of life in hypertrophic cardiomyopathy. Heart (British Cardiac Society) 2026. link 65 Dong Q, Han B, Wang N. Exploratory Mendelian randomization analysis: The genetic susceptibility of CT examination preference and the risk of hypertrophic cardiomyopathy. Medicine 2026. link 66 Ni H, Liang F, Huo H, Feng X, He B. Integrated spatial transcriptomics and single-cell RNA sequencing reveal Lars2-mediated spatiotemporal dynamics of myocardial remodeling in a mouse model of transverse aortic constriction. Frontiers in immunology 2026. link 67 Owens AT, Schuler P, Jiang J, Han X, Hernandez EM, Anderson A et al.. Access Challenges for Septal Reduction Therapy Among Individuals With Obstructive Hypertrophic Cardiomyopathy. Journal of the American Heart Association 2026. link 68 Kaski JP, Kantor PF, Nakano SJ, Olivotto I, Russell MW, Godown J et al.. Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM. Circulation. Heart failure 2026. link 69 Zhang K, Xu T, Heng XY, Lei JZ, Han DS, Huang SH et al.. Galangin 3-methyl ether alleviates mouse hypertrophic cardiomyopathy via targeting HDAC2 and subsequently inactivating the PI3K-AKT signaling pathway. Acta pharmacologica Sinica 2026. link 70 Nassif ME, Garcia-Pavia P, Masri A, Merkely B, Peña-Peña ML, Barriales-Villa R et al.. Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology 2026. link 71 Wagner MJ, Jeewa A, Pidborochynski T, Lemaire-Paquette S, Khoury M, Cunningham C et al.. Modifiable Health Behaviours in Children with HCM: Lessons from the Heart Health Survey. Pediatric cardiology 2026. link 72 Bonacchi G, Del Franco A, Agostoni P, Agricola E, Ammirati E, Baratta P et al.. Baseline clinical profile of patients with obstructive hypertrophic cardiomyopathy in the Italian Mavacamten early access program. International journal of cardiology 2026. link 73 Bjerregaard L, Maron MS, Jensen MSK, Dybro AM, Rasmussen TB, Poulsen SH et al.. Relationship between symptom assessment and cardiopulmonary exercise testing in patients with obstructive hypertrophic cardiomyopathy. International journal of cardiology 2026. link 74 Song H, Ding J, Zhao J, Wang Y, Wu Q, Yang M et al.. Prognostic value of cardiac fibroblast activation heterogeneity assessed by FAPI PET radiomics in hypertrophic cardiomyopathy: a proof-of-concept study. Open heart 2026. link 75 Zhang S, Yuan Q, Zhu Z, Deng L, Nie H, Liang T et al.. Distinct Subgroups and Outcomes in Patients With Hypertrophic Obstructive Cardiomyopathy After Septal Myectomy. The Annals of thoracic surgery 2026. link 76 Qian J, Zhang J, Jiang Q, Wu T. Cost-effectiveness analysis of mavacamten for obstructive hypertrophic cardiomyopathy: a perspective from the Chinese healthcare system. Open heart 2026. link 77 Liu CH, Yao JH, Chen CH, Chen KW, Wu HP. Transient Ventricular Capture Loss Following Alcohol Septal Ablation in Left Bundle Branch Area Pacing: A Case Report. Journal of cardiovascular electrophysiology 2026. link 78 Bjerregaard L, Dybro AM, Saaby L, Poulsen SH, Rasmussen TB, Jensen MSK. Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial. Journal of the American College of Cardiology 2026. link 79 Schamroth Pravda N, Itelman E, Plakht Y, Schifter L, Murad O, Grinberg T et al.. Cardiovascular Magnetic Resonance-based Tissue Characteristics and Clinical Outcomes in Apical Hypertrophic Cardiomyopathy. The American journal of cardiology 2026. link 80 Khaliq IH, Solanki A, Kinno M, Volgman AS, Oktay AA. Challenges in the diagnosis and management of hypertrophic cardiomyopathy and the promise of artificial intelligence. Current problems in cardiology 2026. link 81 Shawki M, Sampaio Rodrigues T, Khabazi KP, Brick C, Teh A, Lim HS et al.. Short-term incidence and risk of atrial fibrillation in patients with hypertrophic cardiomyopathy receiving cardiac myosin inhibitors: A systematic review and meta-analysis. International journal of cardiology 2026. link 82 Dereli Bulut SS, Akcayoz B, Sakci Z, Günay N. Temporal patterns of diastolic and systolic dysfunction in hypertrophic cardiomyopathy assessed by cardiac magnetic resonance (CMR) time-volume parameters. Clinical radiology 2026. link 83 Amano M, Kitaoka H, Yoshikawa Y, Kubo T, Sakata Y, Dohi K et al.. Validation of the 2018 Japanese Circulation Society (JCS)/Japanese Heart Failure Society (JHFS) Guidelines for Preventing Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy. Circulation journal : official journal of the Japanese Circulation Society 2026. link 84 Charron P, Zema C, Cotté FE, Juban A, Schmidt A, Krause T et al.. A nationwide study of the economic burden of obstructive hypertrophic cardiomyopathy in France. European heart journal. Quality of care & clinical outcomes 2026. link 85 Łajczak P, Righetto BB, Obi O, Wijaya P, Sahin OK, Eltawansy S et al.. AI-driven ECG diagnostics: A game-changer for hypertrophic cardiomyopathy. A systematic review and diagnostic test accuracy meta-analysis. Heart & lung : the journal of critical care 2026. link 86 Lee MMY, Goldie FC, Henderson AD, Masri A, Olivotto I, Coats CJ. Efficacy and safety of cardiac myosin inhibitors in obstructive hypertrophic cardiomyopathy: Systematic review and comprehensive frequentist and Bayesian meta-analyses of Phase 3 randomized controlled trials. Progress in cardiovascular diseases 2026. link 87 Zocchi C, Milazzo A, Panichella G, Garofalo M, Fanizzi AI, Ragagnin M et al.. Non-invasive evaluation of left ventricular hemodynamic force abnormalities in hypertrophic cardiomyopathy: Implications for myosin inhibition. International journal of cardiology 2026. link 88 Peters M, Schweitzer M, Galazka P. Multimodality Imaging in Hypertrophic Cardiomyopathy. Heart failure clinics 2026. link 89 Siddiqi AK, Maniya MT, Bilen O, Abdou M, De Cecco CN, Naeem M. Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging for non-sustained ventricular tachycardia and sudden cardiac death in hypertrophic cardiomyopathy: a meta-analysis. European radiology 2026. link 90 Spanjersberg TCF, Hassanzada F, Jongbloed JDH, Dooijes D, van Tintelen JP, Asselbergs FW et al.. Population and family data support TNNT2 p.Arg288Cys as an intermediate effect variant in hypertrophic cardiomyopathy. International journal of cardiology 2026. link 91 Hafeez N, Claggett BL, Owens AT, Helms AS, Saberi S, Lampert R et al.. Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy. JAMA cardiology 2026. link 92 Ma L, Li F, Dong S, Li R. Mavacamten in hypertrophic obstructive cardiomyopathy with hepato-renal comorbidities: A case report. Medicine 2026. link 93 Aman A, Akram A, Akram B, Maham M, Bokhari MZ, Akram A et al.. Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials. Open heart 2025. link 94 Hashim HT, Osama M, Khan MH, Khan S, Rehman N, Ghuraibawi M et al.. Efficacy and safety of radiofrequency ablation for hypertrophic obstructive cardiomyopathy: a meta-analysis. Future cardiology 2025. link 95 Aboutorabi M, Ahmad M, Flora K, Ferreira H, Chiu M, Bray JJH et al.. Direct oral anticoagulants versus vitamin K antagonists in concurrent hypertrophic cardiomyopathy and atrial fibrillation: a meta-analysis. Expert review of cardiovascular therapy 2025. link 96 Otmani Z, Abdrabou N, Elsayed HA, Yassin MNA, Abouzid M, Hindawi MD et al.. The effect of mavacamten on echocardiographic parameters, cardiac function and biomarkers in hypertrophic cardiomyopathy patients, a systematic review and meta-analysis. Indian heart journal 2025. link 97 Papapostolou S, Iles L, O'Brien J, Gutman SJ, Ellims A, Hare J et al.. The Antifibrotic Effects of Eplerenone in Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. JACC. Heart failure 2025. link 98 Sharma AN, Birda A, Park M, Choe S, Salas J, Kincaid C et al.. Insights Into Demographics, Comorbidities, and Risk Factors in Keloids and Hypertrophic Scars: A Retrospective Study. Journal of drugs in dermatology : JDD 2025. link 99 Zhou L, Cai C, Wu R, Qi Y. Effectiveness of scaffolded case-based learning in anesthesiology residency training: a randomized controlled trial. BMC medical education 2025. link 100 Zeng X, Wu H, Wang R, Huang P, Xu X, Zeng Y et al.. Major adverse cardiovascular events after modified morrow surgery in hypertrophic obstructive cardiomyopathy: A 12-year cohort study. International journal of cardiology 2025. link

Original source

[1]
Role of multi-modality cardiac imaging in the management of patients with hypertrophic cardiomyopathy in 2025. A Clinical Consensus Statement of the European Association of Cardiovascular Imaging (EACVI) of the ESC. — Cardim N, Haugaa K, Mohiddin SA, Hinojar R, Hirsch A, Szabo L et al. European heart journal. Cardiovascular Imaging (2026)
[2]
Interventions for Hypertrophic Obstructive Cardiomyopathy: Defining the Gold Standard, Assessing Durability, and Guiding Patient Selection. — Anifowose A, Tagliafierro M, Mahdi G, Hussein S, Baudo M, Caldonazo T et al. Medical sciences (Basel, Switzerland) (2026)
[3]
Impact of preoperative computed tomography planning on surgical outcomes in patients with obstructive hypertrophic cardiomyopathy: A prospective cohort study. — Lee JE, Koo HJ, Lee SA, Hyun J, Yoo JS, Yang DH et al. The Journal of thoracic and cardiovascular surgery (2026)
[4]
Clinical value of the tissue Doppler derived index of myocardial performance (Tei index) in cats with hypertrophic cardiomyopathy. — Naseri A, Ider M, Sahin HB, Durgut MK, Iyigun SS, Guzelbektes H Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology (2026)
[5]
Photon-counting CT myocardial extracellular volume: A non-invasive biomarker for fibrosis in patients with hypertrophic cardiomyopathy. — Gkizas C, Longere B, Bechrouri S, Ridon H, Musso AR, Haidar M et al. Diagnostic and interventional imaging (2026)
[6]
Mavacamten in Obstructive Hypertrophic Cardiomyopathy-A First Australian Experience. — So ACF, Davison KA, Hecker T, Moriswala R, Pasupathy S, Shah RJ et al. Heart, lung & circulation (2026)
[7]
Role of provocation and exercise imaging for the identification of candidates for cardiac myosin inhibitors. — Erzeel J, Dhont S, van Es M, Ulgar D, Bertrand P, Mullens W et al. ESC heart failure (2026)
[8]
Sudden perioperative death post aortic valve replacement with autopsy showing hypertrophic cardiomyopathy in elderly female. — Razak ZA, Westaby J, Sheppard MN International journal of legal medicine (2026)
[9]
Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy. — Kiselev E, Agyapong W, Jürgens B, Mohr E, Chatterjee S, Hunkler HJ et al. British journal of pharmacology (2026)
[10]
Focused Transthoracic Echocardiogram Surveillance Protocol for Hypertrophic Cardiomyopathy Patients on Mavacamten Therapy. — Pearlman A, Hellyer R, Burns C, Medi C, Gray B Heart, lung & circulation (2026)
[11]
The evolving clinical practice of septal reduction therapy in hypertrophic obstructive cardiomyopathy. — Zhang X, Xie Y, Fang L, Xu J, Yang Y, He Z et al. International journal of surgery (London, England) (2026)
[12]
Mavacamten in symptomatic adolescent patients with obstructive hypertrophic cardiomyopathy: design of the phase 3 SCOUT-HCM trial. — Rossano J, Canter C, Wolf C, Favatella N, Lockman J, Puli S et al. American heart journal (2026)
[13]
Application of untargeted plasma metabolomics and machine learning to construct a diagnostic model for hypertrophic cardiomyopathy: a case-control study. — Li R, Wang B, Shan B, Sun M, Ta S, Zhao J et al. Metabolomics : Official journal of the Metabolomic Society (2026)
[14]
Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM. — Wang X, Pabon MA, Makuvire TT, Maimaiti R, Abraham TP, Barriales-Villa R et al. Circulation. Heart failure (2026)
[15]
Genotype-phenotype associations in sarcomeric hypertrophic cardiomyopathy associated with mutations in the MYBPC3 gene: Systematic review and meta-analysis. — Nogueira-Garcia B, Pinheiro D, Gregório C, Caldeira D, Pinto FJ, Brito D Journal of cardiology (2026)
[16]
Impact of centre experience on complete clinical and haemodynamic response after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. — Veselka J, Liebregts M, Cooper R, Faber L, Januska J, Krejci J et al. International journal of cardiology (2026)
[17]
Clinical Outcomes With Mavacamten Use in Patients With Obstructive Hypertrophic Cardiomyopathy Using Real-World Data. — Patel N, Gaonkar M, Pampana A, Shetty NS, Vekariya N, Li P et al. Mayo Clinic proceedings (2026)
[18]
Percutaneous Management of Right Ventricular Outflow Tract Obstruction in an Adult Patient After Atrial Switch: A Case for Targeted Infundibular Ablation. — Osberghaus V, Wustmann K, Heck PB, Georgiev S, Eicken A, Ewert P et al. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026)
[19]
Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy: The EMORI-HCM Trial. — Mohal JS, Whinnett ZI, Mohiddin SA, Malcolmson J, Elliott P, Ormerod JOM et al. Journal of the American College of Cardiology (2026)
[20]
Autosomal recessive hypertrophic cardiomyopathy associated with variants in TRIM63. — Bonanni F, Ballerini A, Gozzini A, Marchi A, Palinkas ED, Barletta V et al. International journal of cardiology (2026)
[21]
Hypertrophic Cardiomyopathy: Patient Selection, Referral Timing, and Advanced Therapy Options. — Abusafia M, Jadam S, Ospina S, Desai MY Heart failure clinics (2026)
[22]
Transcatheter Edge-to-Edge Repair for SAM-Related Mitral Regurgitation in Patients With HCM: The TRANSPARENT Registry. — Testa L, Arzuffi L, Popolo Rubbio A, Brambilla N, Maisano F, Agricola E et al. JACC. Cardiovascular interventions (2026)
[23]
Effect of echocardiographic imaging view and methods on left ventricular wall-thickness measurements in normal cats and cats with hypertrophic cardiomyopathy. — Grosso G, Schober KE Journal of veterinary internal medicine (2026)
[24]
Mavacamten and Aficamten in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Trials. — Fahim M, Eldawud D, Wahadneh O, Wang R, Gorantla A, Sharma N et al. The American journal of cardiology (2026)
[25]
Feasibility of an Individualized Exercise Training Program for Children with Hypertrophic Cardiomyopathy. — Wanner J, Burstein D, Paridon S, Shah M, O'Malley S, Lin KY et al. Pediatric cardiology (2026)
[26]
CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy. — Lin B, Wang J, Li C, Wang S, Shen M, Hu L et al. Circulation (2026)
[27]
Multimodality Imaging in Hypertrophic Cardiomyopathy. — Peters M, Schweitzer M, Galazka P Cardiology clinics (2026)
[28]
miR-144 targets in myocardial hypertrophy and coronary microvascular dysfunction in hypertrophic cardiomyopathy: molecular research meets imaging. — Lombardi M, Barki M, Spartano L, Lazzeroni D, Benedetti G, Pisano A et al. Basic research in cardiology (2026)
[29]
Predictors for increasing genetic testing yields in hypertrophic cardiomyopathy. — Killian M, Ranganathan D, Moore D, Gallagher M, Ochoa JP, Howard S et al. Irish journal of medical science (2026)
[30]
Genetic diversity and molecular mechanisms in hypertrophic cardiomyopathy: toward personalized therapy. — Marwaha K, Mody B, Holland N, Lane M, Shoemake BD, Singh N et al. American journal of physiology. Heart and circulatory physiology (2026)
[31]
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. — Wang A, Garcia-Pavia P, Masri A, Merkely B, Nassif ME, Peña-Peña ML et al. Journal of the American College of Cardiology (2026)
[32]
Feature Tracking-Derived Global Longitudinal Strain Enhances Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy. — Ma X, Tang Y, Chen X, Yang S, Wang J, Yang K et al. JACC. Cardiovascular imaging (2026)
[33]
Model-Based Economic Evaluation of the First-in-Class Myosin Inhibitor Mavacamten Versus Care as Usual in Obstructive Hypertrophic Cardiomyopathy Patients from a Dutch Societal Perspective. — Wiethoff I, Witlox WJA, Evers SMAA, Michels M, Hiligsmann M PharmacoEconomics (2026)
[34]
Coronary artery disease characterization and plaque morphology in patients with hypertrophic cardiomyopathy. — Grinberg T, Aviv Y, Shiyovich A, Vronsky D, Lerman TT, Pravda NS et al. The American journal of medicine (2026)
[35]
Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM. — Bilen O, Adler A, Bastiaenen R, MacNamara JP, Paratz E, Maor E et al. Circulation. Genomic and precision medicine (2026)
[36]
Incremental prognostic value of epicardial adipose tissue volume and thickness assessed by cardiac MRI in hypertrophic cardiomyopathy. — Song Y, Hu M, Ren H, Fang Q, Zheng T, Feng Z et al. European heart journal. Cardiovascular Imaging (2026)
[37]
Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: Long-Term Follow-Up of Deformations and Hemodynamics. — Suwa K, Ohno K, Satoh T, Sato R, Iguchi K, Maekawa Y Journal of magnetic resonance imaging : JMRI (2026)
[38]
Cardiovascular Health and Outcomes in Carriers With Genetic Variants of Hypertrophic Cardiomyopathy. — Patel N, Gaonkar M, Pampana A, Dhaliwal JS, Vekariya N, Shetty NS et al. Mayo Clinic proceedings (2026)
[39]
Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation. — Zampieri M, Saberi S, D'Ascenzi F, Papadakis M, Pelliccia A, Olivotto I European heart journal (2026)
[40]
Heterogeneous Myocardial Adaptation to Pressure Overload Reveals a Spared, Vulnerable Segment Identified by Multiparametric Cardiac MRI. — Koch V, Ochs AT, Martin S, Vogl T, Ochs MM, Leistner DM et al. NMR in biomedicine (2026)
[41]
Incremental Value of NT-proBNP Over HCM-AF Score in Risk Stratification for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. — Gao YP, Fan YT, Cheng XQ, Huang PN, Liu HY, Bi XJ et al. Clinical cardiology (2026)
[42]
Characterising the phenotype and ‍outcomes of cascade-tested relatives of probands with ‍hypertrophic cardiomyopathy. — Chaudhry WR, McWilliam C, Berg J, Choy AM Open heart (2026)
[43]
Effect of mavacamten and disopyramide on left ventricular mechanical dispersion and life-threatening arrhythmia in obstructive hypertrophic cardiomyopathy. — Ozbay B, Wong TC, Estes NAM, Katz WE, Suffoletto MS, Green G et al. European heart journal. Cardiovascular Imaging (2026)
[44]
Discovery of small molecule modulators of the thin filament that alter the contractile profile in a hypertrophic cardiomyopathy engineered tissue model. — Sommese RF, Levi SM, Brown J, Polivkova J, Byrnes LJ, Kue R et al. The Journal of biological chemistry (2026)
[45]
What Do We Know About Hypertrophic Cardiomyopathy in Poland in the Period 2016-2021 Based on Data From the Public Health System? — Niemiec M, Stec M, Grzybowski J, Cegłowska U, Wiśniewska A, Hałgas K et al. International journal of public health (2026)
[46]
Use of artificial intelligence in the multimodal evaluation of ischemia in patients with hypertrophic cardiomyopathy. — Steitieh D, Gupta J, Kim R The international journal of cardiovascular imaging (2026)
[47]
Reverse septal curvature in hypertrophic cardiomyopathy: Implications for function, structure and arrhythmic risk. — Polizzi R, Canciello G, Ordine L, di Napoli S, Pacella D, Moscano L et al. International journal of cardiology (2026)
[48]
Concomitant Mitral Valve Surgery During Surgical Treatment of Hypertrophic Obstructive Cardiomyopathy. — Bové T, Impens L, Leleu J, Timmermans F, François K The American journal of cardiology (2026)
[49]
Prognostic Implications of Mitral Regurgitation Across Hypertrophic Cardiomyopathy Subtypes: A Report From REVEAL-HCM Study. — Obayashi Y, Kato T, Shiomi H, Nakatsuka K, Kitaoka H, Sakata Y et al. Circulation. Heart failure (2026)
[50]
Percutaneous Endocardial Septal Pulsed Field Ablation for Hypertrophic Obstructive Cardiomyopathy: A Case Report. — Tian Y, Zhang H, Yang S, Chu C, Jing H, Gong C et al. Pacing and clinical electrophysiology : PACE (2026)
[51]
Scar architecture as a structural biomarker of ventricular arrhythmias and sudden cardiac death in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance study. — Francia P, Falasconi G, Musumeci MB, Biagini E, Freitas P, Penela D et al. European heart journal. Cardiovascular Imaging (2026)
[52]
Identification of Cuproptosis-Associated Biomarker Candidates in Hypertrophic Cardiomyopathy via Machine Learning and Multi-Omics Integration. — Wang W, Tian Y, Wang C, Yang X Applied biochemistry and biotechnology (2026)
[53]
Mavacamten effectively reduces > 100 mmHg left ventricular outflow tract gradients as early as one week of treatment in obstructive hypertrophic cardiomyopathy. — Nagy V, Rácz G, Takács H, Boda K, Polestyuk B, Schvartz N et al. International journal of cardiology (2026)
[54]
Peak Gradients and Left Ventricular Outflow Tract Area in Hypertrophic Obstructive Cardiomyopathy:A 3-Dimensional Echocardiography Study. — Sharkey A, Ahmed U, Manji AA, Mahmood F, Saeed S, Valencia J et al. Journal of cardiothoracic and vascular anesthesia (2026)
[55]
Integrating ECG Into the Mayo Score Enhances Genotype Prediction in Hypertrophic Cardiomyopathy. — Hiruma T, Inoue S, Dai Z, Nomura S, Kubo T, Sugiura K et al. Journal of the American Heart Association (2026)
[56]
Mechanisms and Therapies of Hypertrophic Cardiomyopathy. — Pietsch N, Singh SR, Carrier L Annual review of physiology (2026)
[57]
A machine Learning-Based risk stratification using CMR volumetric and strain parameters in patients with hypertrophic cardiomyopathy. — Kim H, Song MJ, Kim J, Kim SM The international journal of cardiovascular imaging (2026)
[58]
Transapical beating-heart approach is advantageous for surgical septal reduction therapy in pediatrics. — Chen Y, Lai Y, Fang J, Li R, Yan J, Tan T et al. The Journal of thoracic and cardiovascular surgery (2026)
[59]
Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy. — Reza N, Butzner M, Batra K, Amos Q, Buikema A, Shreay S et al. Journal of the American Heart Association (2026)
[60]
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy. — Masri A, Maron MS, Abraham TP, Nassif ME, Barriales-Villa R, Bilen O et al. JACC. Heart failure (2026)
[61]
Reply to letter to the editor: "Long-term clinical outcomes after alcohol septal ablation for hypertrophic obstructive cardiomyopathy in Japan: a retrospective study". — Matsuda J, Takano H, Imori Y, Ishihara K, Sangen H, Kubota Y et al. Heart and vessels (2026)
[62]
Diagnosis and Treatment Guided by 3D Imaging and Modeling: A W-shaped Interventricular Septal Phenotype in Hypertrophic Obstructive Cardiomyopathy. — Andrushchuk U, Niavyhlas A, Nesterowicz M, Dzieżyk W, Chrostowski T, Sulima D et al. Radiology. Cardiothoracic imaging (2026)
[63]
Non-contrast multimodal cardiac MRI for predicting coronary microvascular dysfunction in patients with hypertrophic cardiomyopathy. — Li J, Zhu L, Liu Y, Han Y, Yuan S, Cao J et al. Magnetic resonance imaging (2026)
[64]
Accelerometry-defined physical activity and quality of life in hypertrophic cardiomyopathy. — Schoonvelde SAC, Zwetsloot PP, Hirsch A, Schinkel AFL, Knackstedt C, Germans T et al. Heart (British Cardiac Society) (2026)
[65]
Exploratory Mendelian randomization analysis: The genetic susceptibility of CT examination preference and the risk of hypertrophic cardiomyopathy. — Dong Q, Han B, Wang N Medicine (2026)
[66]
Integrated spatial transcriptomics and single-cell RNA sequencing reveal Lars2-mediated spatiotemporal dynamics of myocardial remodeling in a mouse model of transverse aortic constriction. — Ni H, Liang F, Huo H, Feng X, He B Frontiers in immunology (2026)
[67]
Access Challenges for Septal Reduction Therapy Among Individuals With Obstructive Hypertrophic Cardiomyopathy. — Owens AT, Schuler P, Jiang J, Han X, Hernandez EM, Anderson A et al. Journal of the American Heart Association (2026)
[68]
Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM. — Kaski JP, Kantor PF, Nakano SJ, Olivotto I, Russell MW, Godown J et al. Circulation. Heart failure (2026)
[69]
Galangin 3-methyl ether alleviates mouse hypertrophic cardiomyopathy via targeting HDAC2 and subsequently inactivating the PI3K-AKT signaling pathway. — Zhang K, Xu T, Heng XY, Lei JZ, Han DS, Huang SH et al. Acta pharmacologica Sinica (2026)
[70]
Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. — Nassif ME, Garcia-Pavia P, Masri A, Merkely B, Peña-Peña ML, Barriales-Villa R et al. Journal of the American College of Cardiology (2026)
[71]
Modifiable Health Behaviours in Children with HCM: Lessons from the Heart Health Survey. — Wagner MJ, Jeewa A, Pidborochynski T, Lemaire-Paquette S, Khoury M, Cunningham C et al. Pediatric cardiology (2026)
[72]
Baseline clinical profile of patients with obstructive hypertrophic cardiomyopathy in the Italian Mavacamten early access program. — Bonacchi G, Del Franco A, Agostoni P, Agricola E, Ammirati E, Baratta P et al. International journal of cardiology (2026)
[73]
Relationship between symptom assessment and cardiopulmonary exercise testing in patients with obstructive hypertrophic cardiomyopathy. — Bjerregaard L, Maron MS, Jensen MSK, Dybro AM, Rasmussen TB, Poulsen SH et al. International journal of cardiology (2026)
[74]
Prognostic value of cardiac fibroblast activation heterogeneity assessed by FAPI PET radiomics in hypertrophic cardiomyopathy: a proof-of-concept study. — Song H, Ding J, Zhao J, Wang Y, Wu Q, Yang M et al. Open heart (2026)
[75]
Distinct Subgroups and Outcomes in Patients With Hypertrophic Obstructive Cardiomyopathy After Septal Myectomy. — Zhang S, Yuan Q, Zhu Z, Deng L, Nie H, Liang T et al. The Annals of thoracic surgery (2026)
[76]
Cost-effectiveness analysis of mavacamten for obstructive hypertrophic cardiomyopathy: a perspective from the Chinese healthcare system. — Qian J, Zhang J, Jiang Q, Wu T Open heart (2026)
[77]
Transient Ventricular Capture Loss Following Alcohol Septal Ablation in Left Bundle Branch Area Pacing: A Case Report. — Liu CH, Yao JH, Chen CH, Chen KW, Wu HP Journal of cardiovascular electrophysiology (2026)
[78]
Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial. — Bjerregaard L, Dybro AM, Saaby L, Poulsen SH, Rasmussen TB, Jensen MSK Journal of the American College of Cardiology (2026)
[79]
Cardiovascular Magnetic Resonance-based Tissue Characteristics and Clinical Outcomes in Apical Hypertrophic Cardiomyopathy. — Schamroth Pravda N, Itelman E, Plakht Y, Schifter L, Murad O, Grinberg T et al. The American journal of cardiology (2026)
[80]
Challenges in the diagnosis and management of hypertrophic cardiomyopathy and the promise of artificial intelligence. — Khaliq IH, Solanki A, Kinno M, Volgman AS, Oktay AA Current problems in cardiology (2026)
[81]
Short-term incidence and risk of atrial fibrillation in patients with hypertrophic cardiomyopathy receiving cardiac myosin inhibitors: A systematic review and meta-analysis. — Shawki M, Sampaio Rodrigues T, Khabazi KP, Brick C, Teh A, Lim HS et al. International journal of cardiology (2026)
[82]
Temporal patterns of diastolic and systolic dysfunction in hypertrophic cardiomyopathy assessed by cardiac magnetic resonance (CMR) time-volume parameters. — Dereli Bulut SS, Akcayoz B, Sakci Z, Günay N Clinical radiology (2026)
[83]
Validation of the 2018 Japanese Circulation Society (JCS)/Japanese Heart Failure Society (JHFS) Guidelines for Preventing Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy. — Amano M, Kitaoka H, Yoshikawa Y, Kubo T, Sakata Y, Dohi K et al. Circulation journal : official journal of the Japanese Circulation Society (2026)
[84]
A nationwide study of the economic burden of obstructive hypertrophic cardiomyopathy in France. — Charron P, Zema C, Cotté FE, Juban A, Schmidt A, Krause T et al. European heart journal. Quality of care & clinical outcomes (2026)
[85]
AI-driven ECG diagnostics: A game-changer for hypertrophic cardiomyopathy. A systematic review and diagnostic test accuracy meta-analysis. — Łajczak P, Righetto BB, Obi O, Wijaya P, Sahin OK, Eltawansy S et al. Heart & lung : the journal of critical care (2026)
[86]
Efficacy and safety of cardiac myosin inhibitors in obstructive hypertrophic cardiomyopathy: Systematic review and comprehensive frequentist and Bayesian meta-analyses of Phase 3 randomized controlled trials. — Lee MMY, Goldie FC, Henderson AD, Masri A, Olivotto I, Coats CJ Progress in cardiovascular diseases (2026)
[87]
Non-invasive evaluation of left ventricular hemodynamic force abnormalities in hypertrophic cardiomyopathy: Implications for myosin inhibition. — Zocchi C, Milazzo A, Panichella G, Garofalo M, Fanizzi AI, Ragagnin M et al. International journal of cardiology (2026)
[88]
Multimodality Imaging in Hypertrophic Cardiomyopathy. — Peters M, Schweitzer M, Galazka P Heart failure clinics (2026)
[89]
Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging for non-sustained ventricular tachycardia and sudden cardiac death in hypertrophic cardiomyopathy: a meta-analysis. — Siddiqi AK, Maniya MT, Bilen O, Abdou M, De Cecco CN, Naeem M European radiology (2026)
[90]
Population and family data support TNNT2 p.Arg288Cys as an intermediate effect variant in hypertrophic cardiomyopathy. — Spanjersberg TCF, Hassanzada F, Jongbloed JDH, Dooijes D, van Tintelen JP, Asselbergs FW et al. International journal of cardiology (2026)
[91]
Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy. — Hafeez N, Claggett BL, Owens AT, Helms AS, Saberi S, Lampert R et al. JAMA cardiology (2026)
[92]
Mavacamten in hypertrophic obstructive cardiomyopathy with hepato-renal comorbidities: A case report. — Ma L, Li F, Dong S, Li R Medicine (2026)
[93]
Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials. — Aman A, Akram A, Akram B, Maham M, Bokhari MZ, Akram A et al. Open heart (2025)
[94]
Efficacy and safety of radiofrequency ablation for hypertrophic obstructive cardiomyopathy: a meta-analysis. — Hashim HT, Osama M, Khan MH, Khan S, Rehman N, Ghuraibawi M et al. Future cardiology (2025)
[95]
Direct oral anticoagulants versus vitamin K antagonists in concurrent hypertrophic cardiomyopathy and atrial fibrillation: a meta-analysis. — Aboutorabi M, Ahmad M, Flora K, Ferreira H, Chiu M, Bray JJH et al. Expert review of cardiovascular therapy (2025)
[96]
The effect of mavacamten on echocardiographic parameters, cardiac function and biomarkers in hypertrophic cardiomyopathy patients, a systematic review and meta-analysis. — Otmani Z, Abdrabou N, Elsayed HA, Yassin MNA, Abouzid M, Hindawi MD et al. Indian heart journal (2025)
[97]
The Antifibrotic Effects of Eplerenone in Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. — Papapostolou S, Iles L, O'Brien J, Gutman SJ, Ellims A, Hare J et al. JACC. Heart failure (2025)
[98]
Insights Into Demographics, Comorbidities, and Risk Factors in Keloids and Hypertrophic Scars: A Retrospective Study. — Sharma AN, Birda A, Park M, Choe S, Salas J, Kincaid C et al. Journal of drugs in dermatology : JDD (2025)
[99]
Effectiveness of scaffolded case-based learning in anesthesiology residency training: a randomized controlled trial. — Zhou L, Cai C, Wu R, Qi Y BMC medical education (2025)
[100]
Major adverse cardiovascular events after modified morrow surgery in hypertrophic obstructive cardiomyopathy: A 12-year cohort study. — Zeng X, Wu H, Wang R, Huang P, Xu X, Zeng Y et al. International journal of cardiology (2025)

Share:Twitter Reddit LinkedIn